Schrodinger Stock: A Rare AI-Adjacent Disruptor Still Not Priced For It (NASDAQ:SDGR)
· seekingalpha.com
Schrödinger’s physics-simulated drug design cuts costs, time, and animal testing. The base case delivers reasonable returns without any rerating. See more here.
Finding a disruptor today is a tough ask because wherever there is a sniff of long-duration AI disruption optionality, the markets are already in. The filter cr...